Physician profile
Karine Toumanian
NPI 1306882675
$15,037.20
in general payments reported to CMS, 2019-2025
48 companies · $5,479 in 2025
The $5,479 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,984 · 2020: $2,386 · 2021: $215 · 2022: $1,095 · 2023: $1,121 · 2024: $757 · 2025: $5,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,337 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,337.17 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,941.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,579.12 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,494.22 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,435.25 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,275.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $947.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $700.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $457.36 | 2019-2025 | Verquvo, Lagevrio, Capvaxive |
| Allergan, INC. | $413.51 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $383.23 | 2025 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $369.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $331.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $323.05 | 2019-2020 | |
| Astellas Pharma US INC | $305.28 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $296.61 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $199.99 | 2023-2025 | |
| Corcept Therapeutics | $182.09 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $165.18 | 2024-2025 | Fanapt |
| Exact Sciences Corporation | $163.32 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $159.38 | 2025 | |
| Tms Neurohealth Centers INC. | $157.60 | 2025 | Tms Neurohealth Centers INC. |
| Eisai INC. | $140.99 | 2020 | |
| Medtronic, INC. | $135.11 | 2023 | Micra |
| Otsuka America Pharmaceutical, INC. | $117.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $114.74 | 2020 | |
| Glaxosmithkline, LLC. | $114.50 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bridgebio Pharma, INC. | $106.93 | 2025 | Attruby |
| Alkermes, INC. | $104.58 | 2019 | |
| Emd Serono, INC. | $99.82 | 2019 | |
| Esperion Therapeutics, INC. | $95.25 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.45 | 2025 | Caplyta |
| Lundbeck LLC | $82.63 | 2025 | Rexulti |
| Scpharmaceuticals INC. | $82.41 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.66 | 2020-2025 | Xifaxan |
| Atricure, INC. | $52.60 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Takeda Pharmaceuticals U.S.A., INC. | $45.52 | 2019-2020 | |
| Gilead Sciences, INC. | $42.63 | 2025 | |
| Janssen Biotech, INC. | $33.30 | 2019 | |
| Inspire Medical Systems, INC. | $33.17 | 2025 | Inspire |
| Photonicare INC | $33.03 | 2025 | Otosight Middle Ear Scope |
| Axsome Therapeutics, INC. | $27.59 | 2025 | Symbravo |
| Xeris Pharmaceuticals, INC. | $25.00 | 2025 | Gvoke Hypopen |
| Viatris Specialty LLC | $23.66 | 2025 | Yupelri |
| Abbott Laboratories | $19.85 | 2025 | Freestyle Libre 3 |
| Intra-Sana Laboratories | $17.83 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Mannkind Corporation | $16.27 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $15.42 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karine Toumanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.